Bridgeway Capital Management LLC Grows Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Bridgeway Capital Management LLC increased its position in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 24.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 109,586 shares of the company’s stock after buying an additional 21,500 shares during the quarter. Bridgeway Capital Management LLC’s holdings in Werewolf Therapeutics were worth $162,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in Werewolf Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock worth $1,040,000 after acquiring an additional 16,569 shares during the period. Northern Trust Corp lifted its position in Werewolf Therapeutics by 7.3% during the 4th quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock worth $362,000 after acquiring an additional 16,640 shares during the period. Bank of New York Mellon Corp lifted its position in Werewolf Therapeutics by 23.1% during the 4th quarter. Bank of New York Mellon Corp now owns 71,300 shares of the company’s stock worth $106,000 after acquiring an additional 13,372 shares during the period. JPMorgan Chase & Co. lifted its position in Werewolf Therapeutics by 372.4% during the 4th quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after acquiring an additional 49,608 shares during the period. Finally, Barclays PLC lifted its position in Werewolf Therapeutics by 130.1% during the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after acquiring an additional 30,990 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Up 2.0%

HOWL opened at $1.02 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The business has a 50 day simple moving average of $0.94 and a 200-day simple moving average of $1.40. The stock has a market capitalization of $45.77 million, a P/E ratio of -0.67 and a beta of 0.48. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $5.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.04. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%. On average, equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. JMP Securities decreased their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush decreased their price objective on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research report on Friday, May 9th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.